Management of residual risk after statin therapy

Area of Science:

• Cardiology
• Lipidology
• Pharmacology

Background:

• Cardiovascular disease (CVD) is a leading global cause of death.
• Lipid parameters like LDL-C and HDL-C are strongly associated with coronary heart disease (CHD) risk.
• Current therapies, primarily statins, do not fully mitigate risk in all patients and can cause intolerance.

Purpose of the Study:

• To review the evidence for additional lipid-altering therapies beyond statins.
• To discuss the advantages and disadvantages of these alternative agents.
• To address unmet needs in managing residual cardiovascular risk.

Main Methods:

• Literature review of clinical trials and observational studies.
• Analysis of lipid intervention strategies.
• Evaluation of efficacy and safety profiles of non-statin lipid-lowering drugs.

Main Results:

• Low-density lipoprotein cholesterol (LDL-C) reduction is a key therapeutic target.
• Several non-statin agents show efficacy in lowering LDL-C and other lipids.
• Patient profiles and specific lipid abnormalities influence treatment selection.

Conclusions:

• Additional lipid-modifying agents are crucial for managing residual CVD risk.
• Treatment decisions should be individualized based on patient factors and lipid profiles.
• Further research is needed to optimize combination therapies for CVD prevention.